Inclusion Criteria:

          -  Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1 -
             T3 (AJCC 6th Edition, see Appendix II), NX/N0, M0, following prior prostate
             radiotherapy.

          -  Karnofsky performance status >80.

          -  Greater than 5 year life expectancy

          -  Greater than 2 years since the original course of radiotherapy.

          -  Absence of distant metastases by radiologic or pathologic assessment.

          -  Absence of lymph node involvement by radiologic or pathologic assessment.

          -  Patients must sign a study-specific informed consent form prior to study entry.

        Exclusion Criteria:

          -  Stage T4 disease (AJCC 6th Edition, see Appendix II).

          -  Less than 2 years since the original course of radiotherapy.

          -  Lymph node involvement (N1).

          -  Evidence of distant metastases (M1).

          -  Radical surgery for carcinoma of the prostate

          -  Previous or concurrent cancers other than basal, in situ, or squamous cell skin
             cancers unless disease-free for ≥ 5 years.

          -  Major medical or psychiatric illness, which in the investigator's opinion, would
             prevent completion of treatment and would interfere with follow-up.

          -  History of inflammatory bowel disease

          -  Late GI or GU Morbidity > Grade 1 from the prior course of radiotherapy